Genmab — August 2015
-
Trafikmæssigt har vi kun gået frem siden vi påtog os tjansen for lidt over et år siden. Vi ligger meget højere end PI nogensinde har gjort før undtaget lige en enkelt periode med aktiespil.
-
Der er ikke meget debat i debatten, men de enkelte indlæg bliver flittigt læst.
-
I de sidste 12 måneder er der dukket flere nye aktiesites op - og der kommer endnu flere i den kommende tid. Hertil er der nu mange aktive aktiegrupper på facebook. På den baggrund er jeg tilfreds med at vi alligevel vokser på trafikken.
-
Men for Søren da...Man skal være god på mobilen, hvis man for alvor skal være med i kampen om brugerne.
-
Det skulle man da mene.
-
Tirrel shared with the viewers the list of companies that are most discussed as takeover targets on the Wall Street for Gilead Sciences, Inc.. This list includes Bristol-Myers Squibb Co (NYSE: BMY), Vertex Pharmaceuticals Incorporated(NASDAQ: VRTX), Intercept Pharmaceuticals Inc (NASDAQ: ICPT) and Celgene Corporation(NASDAQ: CELG). She added that some other smaller companies could find its place on the list.
-
De sidste linjer er de bedste.
-
Jeg hørte Winkel sige i børsen-interwievet, at han forventer afgørelse i begyndelsen af næste år, hvis ikke tidligere, hvis FDA speeder processen op. Så hvis der bevilges PRD en af dagene får vi vel en afgørelse inden nytår, og så kan milepælen jo godt komme med i 15-regnskabet.
-
Gilead BMY opkøbsrygtet har været nævnt flere gange, fx her (bemærk ca 1 år gammelt) http://seekingalpha.com/article/2457025-gilead-lets-make-a-deal men jeg har ikke set noget mere konkret end dette
-
I forbindelse med den seneste artikel i New England Journal of Medicine har tidsskriftet selv tilføjet er "editorial" kommentar om Daratumumab. De er ganske positive.http://www.nejm.org/doi/full/10.1056/NEJMe1509419
-
79% of the patients had disease that was refractory to their most recent therapy, including proteasome inhibitors and immunomodulators. The majority of patients (76%) had also undergone autologous stem-cell transplantation. In the cohort that was treated with daratumumab at a dose of 16 mg per kilogram of body weight, the overall response rate was 36%, including two patients with a complete response and two with a very good partial response
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind